SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis rescheduling could be on the horizon following reports of potential executive action. The community is actively discussing the implications of this policy change, particularly how it might trigger a short squeeze and impact the broader cannabis sector. Some are also pointing to Tilray's 'Liquid Diamond' vapes as a potential catalyst.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending after its earnings report triggered a volatile swing, initially rising on strong AI chip sales and guidance, but then sharply declining during the earnings call. Community discussion revolves around potential profit-taking, concerns about non-AI revenue, and the impact of comments made during the call. Despite strong fundamentals, the stock's reaction highlights the market's sensitivity to AI-related news and broader sector trends.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its cultural significance within the cannabis space and its positioning as a "culture coin" on the Solana network. Discussions also highlight potential synergies with broader cannabis reform and related stocks like $TLRY, with community members emphasizing the project's long-term vision.

Aventus Network

Aventus Network ($AVT) is trending as traders discuss a potential breakout, Polkadot integration, and recent strategic advisory appointment in the UAE. Bullish traders are highlighting its oversold conditions and low market cap as catalysts for a potential rally. Community members are closely monitoring volume and potential new exchange listings.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending amid growing community enthusiasm and strong bullish sentiment, with some drawing comparisons to previous meme coin successes. The community is rallying behind $YEE's potential as an ERC-20 token on Ethereum, emphasizing its momentum and strong fundamentals. Some community members believe $YEE could become a leading narrative in the crypto space.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a potential bidding war with Paramount for Warner Bros. Discovery, with some investors hoping Netflix will abandon the deal and collect a $2.8 billion breakup fee, potentially boosting the stock; community chatter revolves around the deal's implications, regulatory hurdles, and potential impact on Netflix's financials and content strategy.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors weigh its potential amid healthcare sector rotation and anticipation of a dividend payout. Technical analysts point to a possible breakout above the $340 resistance, while some community members speculate on news regarding ACA subsidies and potential DOJ developments as catalysts for a significant move. Despite some bearish sentiment, many see UNH as a long-term hold due to its leadership in the healthcare industry.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors digest better-than-expected earnings and revenue, alongside news of the CEO's upcoming departure which some see as a potential catalyst for innovation. Community discussions revolve around the company's guidance, share buybacks, and the potential for analyst upgrades. Bullish sentiment seems to be building on the prospect of new leadership and continued growth, particularly in the international market.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL is trending following news of a national retail distribution agreement with Walmart, leading to a surge in pre-market activity and attracting attention from momentum traders. Community discussions revolve around the potential for a short squeeze and further upward movement, while some traders are wary of potential pullbacks. The stock's thin float and recent high volatility are also key talking points among investors.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Costco is trending amid discussions around its recent earnings, where the company beat EPS estimates but missed on revenue, leading to mixed reactions from investors. Community members are debating whether the stock's high PE ratio is justified, while others are focused on membership growth and digital sales. Some are speculating about a potential special dividend or stock split to attract more investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Outlook For Cellectar Biosciences

Cellectar Biosciences (CLRB) stock tumbled over 17% on Tuesday after the company announced an agreement with several institutional investors to exercise certain existing warrants for gross proceeds of approximately $5.8 million.Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/377/cellectar-biosciences-inc-enters-into-agreements-to-raise">stated</a> that a total of 1.05 million existing warrants were exercised. The company now intends to use the net proceeds for working capital and general corporate purposes in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.The capital raise comes on the heels of Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/376/cellectar-biosciences-announces-european-medicines-agency">announcing</a> that it intends to submit a conditional marketing authorization application to the European Medicines Agency for Iopofosine I 131 as a treatment for refractory Waldenstrom macroglobulinemia in early 2026, following advice from the agency’s Scientific Advice Working Party (SAWP).The company stated that it anticipates European Approval by 2027 and commercial availability of the therapy in the 30 countries represented by the EMA in the same year.“We believe this regulatory success is substantial as it further supports Cellectar’s plans to pursue worldwide approval, including a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) under an accelerated approval pathway,” CEO James Caruso said on Monday, while noting that an NDA submission is contingent upon the company obtaining additional funding to initiate a confirmatory trial.Oppenheimer, which has a ‘Perform rating’ on <a href="https://stocktwits.com/symbol/CLRB">CLRB shares</a>, subsequently noted that the news is a substantial positive catalyst that should bolster the company’s efforts to partner the Iopofosine I 131 program.On Stocktwits, retail sentiment around CLRB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1372/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_11_30_27_AM_png_09a789f2e6.webp" alt="CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1372" height="132"><figcaption>CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the decline in the stock price.<stembedurl>https://stocktwits.com/EvenBetter99/message/631308393</stembedurl>Another user expressed hopes about an impending rally in the shares.<stembedurl>https://stocktwits.com/Slab6/message/631300689</stembedurl>CLRB stock is down 43% this year and approximately 92% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 

Equity

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 


All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Anixa Biosciences (ANIX) This Year?

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

4 Medical Product Stocks to Watch From a Challenging Industry

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Cellectar Biosciences Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$3.78
Prev Close	$4.02
Open	$4.00
Dividend Yield	0.00%
50-Day Moving Average	$3.87
Beta	0.90
Avg. Volume	76,542.00
PE Ratio	-0.36

52-Week High	$20.59
52-Week Low	$2.71
Market Capitalization	$17.05M
EPS (Annual)	-$41.89
Price to Book	1.61
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CLRB
Cellectar Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLRB News

CLRBCellectar Biosciences Inc